US Pharma MarketingAnother I&I biotech, Gerhart-led cAMPfield, draws top-tier investors in $180M Series A
San Diego Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug approvals: What’s…
The money continues to flow for drug development startups that are working on inflammatory and immunology medicines licensed from other companies.
A new San Diego biotech called cAMPfield Therapeutics is the latest to secure backing ...
Source: Endpoints News